TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model

Hiroyuki Inoue, Mutsunori Iga, Meng Xin, Saori Asahi, Takafumi Nakamura, Ryo Kurita, Masaharu Nakayama, Yukoh Nakazaki, Koichi Takayama, Yoichi Nakanishi, Kenzaburo Tani

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: Transduction of the granulocyte-macrophage colony stimulating factor (GM-CSF) gene into mouse tumor cells abrogates their tumorigenicity in vivo. Our previous report demonstrated that gene transduction of GM-CSF with either TARC or RANTES chemokines suppressed in vivo tumor formation. In this paper, we examined whether the addition of either recombinant TARC or RANTES proteins to irradiated GM-CSF-transduced tumor vaccine cells enhanced antitumor immunity against established mouse tumor models to examine its future clinical application. Materials and methods: Three million irradiated WEHI3B cells retrovirally transduced with murine GM-CSF cDNA in combination with either recombinant TARC or RANTES were subcutaneously inoculated into syngeneic WEHI3B-preestablished BALB/c mice. Results: Vaccinations were well tolerated. Mice treated with GM-CSF-transduced cells and the chemokines demonstrated significantly longer survival than mice treated with GM-CSF-transduced cells alone. Splenocytes harvested from mice treated with the former vaccines produced higher levels of IL-4, IL-6, IFN-γ, and TNF-α, suggesting enhanced innate and adaptive immunity. Immunohistochemical analysis of tumor sections after vaccination revealed a more significant contribution of CD4+ and CD8+ T cells to tumor repression in the combined vaccine groups than controls. Conclusions: TARC and RANTES enhance the immunological antitumor effect induced by GM-CSF in mouse WEHI3B tumor models and may be clinically useful.

Original languageEnglish
Pages (from-to)1399-1411
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume57
Issue number9
DOIs
Publication statusPublished - Sep 1 2008

Fingerprint

Chemokine CCL5
Cancer Vaccines
Granulocyte-Macrophage Colony-Stimulating Factor
Immunity
Neoplasms
Chemokines
Vaccination
Combined Vaccines
Adaptive Immunity
Innate Immunity
Interleukin-4
Genes
Interleukin-6
Vaccines
Complementary DNA
T-Lymphocytes
Control Groups

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. / Inoue, Hiroyuki; Iga, Mutsunori; Xin, Meng; Asahi, Saori; Nakamura, Takafumi; Kurita, Ryo; Nakayama, Masaharu; Nakazaki, Yukoh; Takayama, Koichi; Nakanishi, Yoichi; Tani, Kenzaburo.

In: Cancer Immunology, Immunotherapy, Vol. 57, No. 9, 01.09.2008, p. 1399-1411.

Research output: Contribution to journalArticle

Inoue, H, Iga, M, Xin, M, Asahi, S, Nakamura, T, Kurita, R, Nakayama, M, Nakazaki, Y, Takayama, K, Nakanishi, Y & Tani, K 2008, 'TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model', Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1399-1411. https://doi.org/10.1007/s00262-008-0476-7
Inoue, Hiroyuki ; Iga, Mutsunori ; Xin, Meng ; Asahi, Saori ; Nakamura, Takafumi ; Kurita, Ryo ; Nakayama, Masaharu ; Nakazaki, Yukoh ; Takayama, Koichi ; Nakanishi, Yoichi ; Tani, Kenzaburo. / TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. In: Cancer Immunology, Immunotherapy. 2008 ; Vol. 57, No. 9. pp. 1399-1411.
@article{0ea8672ba04a43d2bfaaf1e5aa4b3bd4,
title = "TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model",
abstract = "Introduction: Transduction of the granulocyte-macrophage colony stimulating factor (GM-CSF) gene into mouse tumor cells abrogates their tumorigenicity in vivo. Our previous report demonstrated that gene transduction of GM-CSF with either TARC or RANTES chemokines suppressed in vivo tumor formation. In this paper, we examined whether the addition of either recombinant TARC or RANTES proteins to irradiated GM-CSF-transduced tumor vaccine cells enhanced antitumor immunity against established mouse tumor models to examine its future clinical application. Materials and methods: Three million irradiated WEHI3B cells retrovirally transduced with murine GM-CSF cDNA in combination with either recombinant TARC or RANTES were subcutaneously inoculated into syngeneic WEHI3B-preestablished BALB/c mice. Results: Vaccinations were well tolerated. Mice treated with GM-CSF-transduced cells and the chemokines demonstrated significantly longer survival than mice treated with GM-CSF-transduced cells alone. Splenocytes harvested from mice treated with the former vaccines produced higher levels of IL-4, IL-6, IFN-γ, and TNF-α, suggesting enhanced innate and adaptive immunity. Immunohistochemical analysis of tumor sections after vaccination revealed a more significant contribution of CD4+ and CD8+ T cells to tumor repression in the combined vaccine groups than controls. Conclusions: TARC and RANTES enhance the immunological antitumor effect induced by GM-CSF in mouse WEHI3B tumor models and may be clinically useful.",
author = "Hiroyuki Inoue and Mutsunori Iga and Meng Xin and Saori Asahi and Takafumi Nakamura and Ryo Kurita and Masaharu Nakayama and Yukoh Nakazaki and Koichi Takayama and Yoichi Nakanishi and Kenzaburo Tani",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s00262-008-0476-7",
language = "English",
volume = "57",
pages = "1399--1411",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model

AU - Inoue, Hiroyuki

AU - Iga, Mutsunori

AU - Xin, Meng

AU - Asahi, Saori

AU - Nakamura, Takafumi

AU - Kurita, Ryo

AU - Nakayama, Masaharu

AU - Nakazaki, Yukoh

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

AU - Tani, Kenzaburo

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Introduction: Transduction of the granulocyte-macrophage colony stimulating factor (GM-CSF) gene into mouse tumor cells abrogates their tumorigenicity in vivo. Our previous report demonstrated that gene transduction of GM-CSF with either TARC or RANTES chemokines suppressed in vivo tumor formation. In this paper, we examined whether the addition of either recombinant TARC or RANTES proteins to irradiated GM-CSF-transduced tumor vaccine cells enhanced antitumor immunity against established mouse tumor models to examine its future clinical application. Materials and methods: Three million irradiated WEHI3B cells retrovirally transduced with murine GM-CSF cDNA in combination with either recombinant TARC or RANTES were subcutaneously inoculated into syngeneic WEHI3B-preestablished BALB/c mice. Results: Vaccinations were well tolerated. Mice treated with GM-CSF-transduced cells and the chemokines demonstrated significantly longer survival than mice treated with GM-CSF-transduced cells alone. Splenocytes harvested from mice treated with the former vaccines produced higher levels of IL-4, IL-6, IFN-γ, and TNF-α, suggesting enhanced innate and adaptive immunity. Immunohistochemical analysis of tumor sections after vaccination revealed a more significant contribution of CD4+ and CD8+ T cells to tumor repression in the combined vaccine groups than controls. Conclusions: TARC and RANTES enhance the immunological antitumor effect induced by GM-CSF in mouse WEHI3B tumor models and may be clinically useful.

AB - Introduction: Transduction of the granulocyte-macrophage colony stimulating factor (GM-CSF) gene into mouse tumor cells abrogates their tumorigenicity in vivo. Our previous report demonstrated that gene transduction of GM-CSF with either TARC or RANTES chemokines suppressed in vivo tumor formation. In this paper, we examined whether the addition of either recombinant TARC or RANTES proteins to irradiated GM-CSF-transduced tumor vaccine cells enhanced antitumor immunity against established mouse tumor models to examine its future clinical application. Materials and methods: Three million irradiated WEHI3B cells retrovirally transduced with murine GM-CSF cDNA in combination with either recombinant TARC or RANTES were subcutaneously inoculated into syngeneic WEHI3B-preestablished BALB/c mice. Results: Vaccinations were well tolerated. Mice treated with GM-CSF-transduced cells and the chemokines demonstrated significantly longer survival than mice treated with GM-CSF-transduced cells alone. Splenocytes harvested from mice treated with the former vaccines produced higher levels of IL-4, IL-6, IFN-γ, and TNF-α, suggesting enhanced innate and adaptive immunity. Immunohistochemical analysis of tumor sections after vaccination revealed a more significant contribution of CD4+ and CD8+ T cells to tumor repression in the combined vaccine groups than controls. Conclusions: TARC and RANTES enhance the immunological antitumor effect induced by GM-CSF in mouse WEHI3B tumor models and may be clinically useful.

UR - http://www.scopus.com/inward/record.url?scp=45849101661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849101661&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0476-7

DO - 10.1007/s00262-008-0476-7

M3 - Article

C2 - 18286286

AN - SCOPUS:45849101661

VL - 57

SP - 1399

EP - 1411

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -